X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (56621) 56621
Book Chapter (211) 211
Publication (89) 89
Dissertation (35) 35
Conference Proceeding (33) 33
Government Document (28) 28
Magazine Article (22) 22
Book / eBook (14) 14
Web Resource (8) 8
Report (7) 7
Streaming Video (5) 5
Newsletter (3) 3
Book Review (2) 2
Newspaper Article (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (42190) 42190
oncology (30323) 30323
phase-ii (25120) 25120
female (19210) 19210
phase-ii trial (15878) 15878
male (15789) 15789
chemotherapy (14861) 14861
cancer (13837) 13837
middle aged (13820) 13820
aged (12534) 12534
adult (11242) 11242
treatment outcome (9851) 9851
antineoplastic combined chemotherapy protocols - therapeutic use (8873) 8873
animals (8271) 8271
antineoplastic agents - therapeutic use (7928) 7928
pharmacology & pharmacy (7228) 7228
clinical trials, phase ii as topic (6288) 6288
care and treatment (6253) 6253
therapy (5791) 5791
prognosis (5034) 5034
cisplatin (5024) 5024
survival (4640) 4640
aged, 80 and over (4553) 4553
trial (4516) 4516
radiotherapy (4367) 4367
carcinoma (4315) 4315
research (4200) 4200
hematology (4189) 4189
medicine & public health (4005) 4005
surgery (3927) 3927
tumors (3915) 3915
clinical trials (3851) 3851
neoplasm staging (3753) 3753
metastasis (3728) 3728
retrospective studies (3683) 3683
disease-free survival (3676) 3676
combined modality therapy (3559) 3559
analysis (3535) 3535
survival rate (3353) 3353
survival analysis (3336) 3336
health aspects (3311) 3311
clinical trials as topic (3285) 3285
drug therapy (3225) 3225
hematology, oncology and palliative medicine (3195) 3195
antineoplastic combined chemotherapy protocols - adverse effects (3154) 3154
mice (3145) 3145
combination (3123) 3123
antineoplastic agents - pharmacology (3080) 3080
lung neoplasms - drug therapy (3078) 3078
paclitaxel (2978) 2978
cell line, tumor (2928) 2928
expression (2877) 2877
breast cancer (2840) 2840
breast neoplasms - drug therapy (2780) 2780
gemcitabine (2771) 2771
immunotherapy (2726) 2726
randomized controlled trials as topic (2718) 2718
radiation-therapy (2707) 2707
cell lung-cancer (2699) 2699
drug administration schedule (2592) 2592
antineoplastic agents - administration & dosage (2552) 2552
medicine, research & experimental (2478) 2478
docetaxel (2468) 2468
antineoplastic agents - adverse effects (2458) 2458
neoplasms - drug therapy (2430) 2430
open-label (2415) 2415
double-blind (2408) 2408
bevacizumab (2376) 2376
apoptosis (2357) 2357
toxicity (2333) 2333
clinical trials, phase iii as topic (2330) 2330
dose-response relationship, drug (2323) 2323
efficacy (2316) 2316
antineoplastic agents (2291) 2291
deoxycytidine - analogs & derivatives (2291) 2291
neoplasm metastasis (2286) 2286
cancer therapies (2275) 2275
cisplatin - administration & dosage (2184) 2184
review (2180) 2180
patients (2178) 2178
breast-cancer (2173) 2173
antibodies, monoclonal - therapeutic use (2169) 2169
carcinoma, non-small-cell lung - drug therapy (2151) 2151
disease progression (2134) 2134
randomized-trial (2118) 2118
follow-up studies (2104) 2104
growth-factor receptor (2065) 2065
antineoplastic combined chemotherapy protocols - administration & dosage (2056) 2056
5-fluorouracil (2040) 2040
randomized phase-ii (2010) 2010
clinical trials, phase i as topic (1993) 1993
antimitotic agents (1979) 1979
adolescent (1958) 1958
mutation (1945) 1945
radiology, nuclear medicine & medical imaging (1940) 1940
risk factors (1936) 1936
time factors (1912) 1912
carboplatin (1899) 1899
1st-line treatment (1896) 1896
endothelial growth-factor (1894) 1894
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (54929) 54929
French (928) 928
German (686) 686
Japanese (405) 405
Spanish (129) 129
Chinese (69) 69
Italian (64) 64
Polish (56) 56
Russian (33) 33
Hungarian (17) 17
Korean (15) 15
Portuguese (14) 14
Turkish (11) 11
Czech (10) 10
Dutch (4) 4
Lithuanian (3) 3
Norwegian (2) 2
Esperanto (1) 1
Finnish (1) 1
Hebrew (1) 1
Serbian (1) 1
Slovenian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Circulation, ISSN 0009-7322, 04/2013, Volume 127, Issue 15, pp. 1630 - 1635
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 09/2018, Volume 13, Issue 9, pp. e178 - e181
Journal Article
Journal Article
Blood, ISSN 1528-0020, 2017, Volume 130, Issue 25, pp. 2709 - 2717
Patients with R/R ALCL who achieved CR with brentuximab vedotin had 79% OS and 57% PFS at 5 years, with median response duration not reached. An estimated 91%... 
SURVIVAL | PHASE-II | PROJECT | HEMATOLOGY | TRANSPLANTATION | Clinical Trials and Observations
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2016, Volume 75, Issue 1, pp. 83 - 98.e4
Background Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, has demonstrated efficacy and safety in patients with moderate to severe plaque... 
Dermatology | pooled analysis | phase II studies | phase III studies | psoriasis | secukinumab | long-term safety | Phase III studies | Secukinumab | Long-term safety | Pooled analysis | Psoriasis | Phase II studies | CONTROLLED-TRIAL | CONFIDENCE-INTERVALS | FOLLOW-UP | RISK | long | DERMATOLOGY | LONGITUDINAL ASSESSMENT | CANDIDA-ALBICANS | REGISTRY PSOLAR | DISEASE | DOUBLE-BLIND | HOST-DEFENSE | term safety | Severity of Illness Index | Etanercept - adverse effects | Psoriasis - drug therapy | Etanercept - administration & dosage | Mental Disorders - chemically induced | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Infection - chemically induced | Randomized Controlled Trials as Topic | Clinical Trials, Phase III as Topic | Neoplasms - chemically induced | Interleukin-17 - antagonists & inhibitors | Time Factors | Antibodies, Monoclonal - administration & dosage | Adult | Female | Immunosuppressive Agents - adverse effects | Inflammatory Bowel Diseases - chemically induced | Cardiovascular Diseases - chemically induced | Neutropenia - chemically induced | Immunosuppressive Agents - administration & dosage | Clinical Trials, Phase II as Topic | Medical research | Care and treatment | Interleukins | Clinical trials | Monoclonal antibodies | Medicine, Experimental | Pharmaceutical industry | Consulting services
Journal Article
Chemical science (Cambridge), ISSN 2041-6539, 2018, Volume 9, Issue 4, pp. 790 - 810
The folate receptor (FR) is an important biomarker for many cancers, and its overexpression on tumours can be exploited for targeted therapy, diagnosis and... 
PHASE-II TRIAL | TUMOR-THERAPY | IN-VIVO | BIOLOGICAL EVALUATION | OVARIAN-CANCER | SPECTROSCOPIC PROBES | ANTITUMOR-ACTIVITY | NEW-GENERATION | FOLIC-ACID | PRECLINICAL EVALUATION | CHEMISTRY, MULTIDISCIPLINARY | Conjugates | Imaging | Vitamin B | Diagnostic software | Biomarkers | Antibodies | Diagnostic systems | Nanotechnology
Journal Article